TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Talecris Infusion Could Save or Sink Grifols EP Vantage submits:Monday’s announcement that Grifols (GIKLY.PK) will be acquiring Talecris Biotherapeutics (TLCR) shows that size does matter, at least when it comes to blood products. The rationale for the deal appears to be the increasing competition in the blood plasma world, and, as such, the companies that can drive economies of scale should stand a better chance of succeeding. Grifols will be paying $3.2bn for Talecris in a mixture of cash and shares, with the $26.16 per share price tag being made up of $19 in cash and the rest in non-voting shares. Investors, however, reacted negatively to the empire-expanding move, pushing shares in Grifols down by 7% by late afternoon trading to €8.61.Complete Story » seekingalpha.com |
Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2010 on August 9, 2010 (Business Wire) BOULDER, Colo.----Array BioPharma Inc. will report financial results for the fourth quarter and full year of fiscal 2010 on Monday, August 9, 2010, and will hold a conference call on Tuesday, August 10, 2010 at 9:00 a.m. eastern time to discuss these results. us.rd.yahoo.com |
Cephalon CEO to Take Medical Leave Cephalon Inc. said Chairman and Chief Executive Frank Baldino Jr. will take a temporary medical leave of absence and is expected to return later this year. online.wsj.com |
Insurer Alters Way to Pay Cancer Docs In the latest experiment aimed at curbing health-care costs, UnitedHealth Group is altering the way cancer specialists are paid. online.wsj.com |
GM IPO Frenzy Fails to Ignite Biotech Offerings The Burrill Report submits: By Michael FitzhughInvestor enthusiasm for the oversubscribed $20 billion General Motors (GM) initial public offering failed to carry over to the biotech sector where a flurry of issues raced to capture some of the excitement sparked by the carmaker’s record offering before the holiday lull. IPOs by Zogenix (ZGNX) and Anacor Pharmaceuticals (ANAC) here, as well as Zealand Pharma in Europe, all debuted to tepid market interest, each pricing well below what company managers hoped to fetch. Complete Story » seekingalpha.com |